Our company’s shared commitment to corporate responsibility (CR) rests with every Novartis associate. Across Novartis, we aim for transparent reporting of annual targets and long-term objectives, as well as to incentivize management and associates to create sustainable value for Novartis in all areas of our business, including corporate responsibility.
CR is endorsed and ingrained at the highest level in the company. The Governance, Nomination and Corporate Responsibilities Committee oversees our company’s strategy and governance on corporate responsibility and key CR issues that may affect the company’s business and reputation.
The members of the Executive Committee of Novartis (ECN) include CR objectives in their balanced scorecard, which is used to determine their compensation. The Chief Executive Officer (CEO) has specific personal CR objectives.
Juergen Brokatzky-Geiger, Global Head of Corporate Responsibility, is fully dedicated to supporting our company-wide CR efforts and better coordinating and leading our many ongoing activities.
An Access to Medicine Committee has been established to specifically assess opportunities to expand access to medicines and treatments, especially in underserved communities; set and monitor targets related to access; and share best practices from across the company. The Access to Medicine Committee is chaired by the CEO and includes high-level commercial representatives from each of our major businesses; it meets three times per year.
Our broader CR efforts are driven by a team of senior leaders comprising the Corporate Responsibility Board. Led by Juergen Brokatzky-Geiger, the CR Board has a focused mandate to advance strategy and programs in our two focus areas: expanding access to healthcare and doing business responsibly. The CR Board is responsible for making recommendations to the Executive Committee of Novartis on strategy, targets, policies, materiality and stakeholder engagement in these two areas. The CR Board is also tasked with facilitating information-sharing between other CR-related governance bodies, such as the Health, Safety and Environment Steering Committee, the Compliance Steering Committee and the Access to Medicine Committee. The CR Board includes representatives from key businesses and functions related to CR, and meets three times annually.